معرفی
Professor Steve Wilton holds the Foundation Chair of Molecular Therapy at Murdoch University, serving as Deputy Director of the Personalised Medicine Centre within the Health Futures Institute and Director of the Perron Institute for Neurological and Translational Science. He pioneered antisense oligonucleotide therapies for Duchenne muscular dystrophy, resulting in three FDA-approved drugs treating over 25% of cases.
Education:
- PhD in Molecular Biology/Biochemistry, University of Adelaide (1979-1983)
- Bachelor of Science in Biochemistry, University of Adelaide (1975-1978)
His research focuses on developing antisense therapies for genetic disorders through RNA splicing modulation. He designed eteplirsen (FDA-approved 2016), golodirsen (2019), and casimersen (2021) for Duchenne muscular dystrophy, with ongoing work expanding to cystic fibrosis, motor neurone disease, Alzheimer's, and neuroinflammatory conditions. His group operates at the intersection of molecular medicine and precision therapeutics.
Awards:
- Officer of the Order of Australia (2021)
- Paul Harris Fellow (2009)
- Fellow of the Australian Academy of Health and Medical Sciences (2024)
Professor Wilton has secured significant research funding including a $500,000 grant for chronic lung disease therapy and leads collaborative networks for rare disease research. His teams at Murdoch University and the Perron Institute drive translational research from bench to bedside, focusing on novel oligonucleotide-based treatments for previously untreatable genetic conditions.